Piyasa Haberleri

En güncel finans ve ekonomi haberlerini, piyasa gelişmelerini, raporları ve analizleri PipVero’da takip edin.

Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Here's Why Integra LifeSciences (IART) is a Strong Momentum Stock

Here's Why Integra LifeSciences (IART) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

İlgili Semboller 1
IART IART
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
Yorum Yap
Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Here's Why CBOE Global (CBOE) is a Strong Momentum Stock

Here's Why CBOE Global (CBOE) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

İlgili Semboller 1
CBOE CBOE
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
Yorum Yap
Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Should Investors Buy ST for Growth Despite Its Heavy Debt Burden?

Should Investors Buy ST for Growth Despite Its Heavy Debt Burden?

Sensata's broad-based growth, margin gains and stronger cash flow support the case, but heavy debt and cyclical risks may limit upside after the rally.

İlgili Semboller 1
ST ST
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
Yorum Yap
Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

İlgili Semboller 1
CORT CORT
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
Yorum Yap
Kaynak: Proactive Investors Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
CVS Health tops second-quarter estimates, raises full-year profit outlook

CVS Health tops second-quarter estimates, raises full-year profit outlook

CVS Health Corp (NYSE:CVS) reported second-quarter revenue and profit that beat Wall Street estimates on Wednesday, and raised its full-year adjusted earnings guidance, though cautious guidance pressured shares. Revenue rose 7.3% year-over-year to $106.1 billion, above analyst estimates of $100.11 billion.

İlgili Semboller 1
CVS CVS
Kaynak: Proactive Investors
Kaynağı Ziyaret Et
Yorum Yap
Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Countdown to Axsome (AXSM) Q2 Earnings: Wall Street Forecasts for Key Metrics

Countdown to Axsome (AXSM) Q2 Earnings: Wall Street Forecasts for Key Metrics

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Axsome (AXSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.

İlgili Semboller 1
AXSM AXSM
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
Yorum Yap
Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Forum Energy Technologies, Inc. (FET) Hit a 52 Week High, Can the Run Continue?

Forum Energy Technologies, Inc. (FET) Hit a 52 Week High, Can the Run Continue?

Forum Energy (FET) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

İlgili Semboller 1
FET FET
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
Yorum Yap
Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Unlocking FMC (FMC) International Revenues: Trends, Surprises, and Prospects

Unlocking FMC (FMC) International Revenues: Trends, Surprises, and Prospects

Evaluate FMC's (FMC) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

İlgili Semboller 1
FMC FMC
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
Yorum Yap
Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Curious about Reinsurance Group (RGA) Q2 Performance? Explore Wall Street Estimates for Key Metrics

Curious about Reinsurance Group (RGA) Q2 Performance? Explore Wall Street Estimates for Key Metrics

Get a deeper insight into the potential performance of Reinsurance Group (RGA) for the quarter ended June 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

İlgili Semboller 1
RGA RGA
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
Yorum Yap